HRP20100240T1 - Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus - Google Patents

Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus Download PDF

Info

Publication number
HRP20100240T1
HRP20100240T1 HR20100240T HRP20100240T HRP20100240T1 HR P20100240 T1 HRP20100240 T1 HR P20100240T1 HR 20100240 T HR20100240 T HR 20100240T HR P20100240 T HRP20100240 T HR P20100240T HR P20100240 T1 HRP20100240 T1 HR P20100240T1
Authority
HR
Croatia
Prior art keywords
seq
polypeptide
sequence
amino acid
immunogen
Prior art date
Application number
HR20100240T
Other languages
English (en)
Inventor
S. Anderson Annaliesa
Ute Jansen Kathrin
Kelly Rosemarie
D. Schultz Loren
L. Montgomery Donna
L. Mcclements William
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100240(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20100240T1 publication Critical patent/HRP20100240T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polipeptidni imunogen, naznačen time što sadrži aminokiselinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1, pri čemu navedeni polipeptid osigurava zaštitni imunitet protiv S. aureus i pri čemu, ako je prisutno jedna ili više dodatnih polipeptidnih regija, tada navedene dodatne regije ne osiguravaju karboksil terminus koji sadrži aminokiseline 609-645 sekvence SEQ ID NO: 2. Patent sadrži još 30 patentnih zahtjeva.

Claims (31)

1. Polipeptidni imunogen, naznačen time što sadrži aminokiselinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1, pri čemu navedeni polipeptid osigurava zaštitni imunitet protiv S. aureus i pri čemu, ako je prisutno jedna ili više dodatnih polipeptidnih regija, tada navedene dodatne regije ne osiguravaju karboksil terminus koji sadrži aminokiseline 609-645 sekvence SEQ ID NO: 2.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 90% identična sekvenci SEQ ID NO: 3 ili njenog fragmenta koji sadrži aminokielinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1.
3. Polipeptid prema patentnom zahtjevu 2, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 94% identična sekvenci SEQ ID NO: 3, ili njenog fragmenta koji sadrži aminokiselinsku sekvencu koja je najmanje 94% identična sekvenci SEQ ID NO: 1.
4. Polipeptid prema patentnom zahtjevu 3, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 94% identična sekvenci SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time što je navedeni polipeptid - SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42; ili se razlikuje od navedenih sekvenci prema maksimalno 25 aminokiselinskih zamjena.
6. Polipeptid prema patentnom zahtjevu 5, naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42, ili se razlikuje od navedenih sekvenci prema maksimalno 10 aminokiselinskih zamjena.
7. Polipeptid prema patentnom zahtjevu 6, naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42, ili se razlikuje od navedenih sekvenci prema maksimalno 5 aminokiselinskih zamjena.
8. Polipeptid prema patentnom zahtjevu 1 naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42.
9. Polipeptid prema patentnom zahtjevu 1 naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence od SEQ ID NO 1, 3, 7, 17, 20 ili 42 i do 20 dodatnih aminokiselina.
10. Polipeptid prema patentnom zahtjevu 5, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence SEQ ID NO 7, 17 ili 20.
11. Polipeptid prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što mu nedostaju svi, ili većina, drugih polipeptida sa kojim je ovaj polipeptid prirodno povezan.
12. Imunogen, naznačen time što se sastoji od polipeptida prema bilo kojem prethodnom patentnom zahtjevu, pri čemu se navedeni imunogen sastoji od navedene aminokiselinske sekvence i jedne ili više dodatnih regija ili grupa kovalentno vezanih za navedenu sekvencu na karboksil terminusu ili amino terminusu, pri čemu je svaka regija ili grupa nezavisno izabrana od regija ili grupe koji imaju najmanje jedno od slijedećih svojstava: pojačavaju imunitetni odgovor, olakšavaju pročišćavanje ili omogućavaju stabilnost polipeptida.
13. Kompozicija koja je sposobna da inducira zaštitni imunitetni odgovor kod pacijenta, naznačena time što sadrži imunitetno efikasnu količinu imunogena prema bilo kojem od patentnih zahtjeva 1-12 i farmaceutski prihvatljiv nosač.
14. Kompozicija prema patentnom zahtjevu 13, naznačena time što navedena kompozicija dalje sadrži adjuvant.
15. Nukleinska kiselina, naznačena time što sadrži rekombinantni gen koji sadrži nukleotidnu sekvencu koja kodira polipeptidni imunogen prema bilo kojem od patentnih zahtjeva 1-10.
16. Nukleinska kiselina prema patentnom zahtjevu 15, naznačena time što rekombinantni gen ne kodira sekvencu staničnog signalnog peptida i ne kodira signalnu sekvencu za sortiranje staničnog zida.
17. Nukleinska kiselina prema patentnom zahtjevu 16, naznačena time što navedeni rekombinantni gen sadrži jedan ili više kodona optimiziranih za ekspresiju kvasca.
18. Nukleinska kiselina prema patentnom zahtjevu 17, naznačena time što je navedena nukleotidna sekvenca najmanje 50% kodon-optimizirana za ekspresiju u kvascu.
19. Nukleinska kiselina prema patentnom zahtjevu 16, naznačena time što je navedena nukleotidna sekvenca izabrana iz grupe koju čine: SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52 i SEQ ID NO: 53.
20. Nukleinska kiselina prema patentnom zahtjevu 15 ili 19, naznačena time što je navedena nukleinska kiselina - ekspresioni vektor.
21. Rekombinantna stanica, naznačena time što sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 15-20.
22. Postupak za pripremu S. aureus polipeptida koji osigurava zaštitni imunitet, naznačen time što sadrži slijedeće korake: (a) rast rekombinantne stanice prema patentnom zahtjevu 21 pod uvjetima u kojima je polipeptid prema bilo kojem od patentnih zahtjeva 1 do 11 eksprimiran; i (b) pročišćavanje navedenog peptida.
23. Postupak prema patentnom zahtjevu 22, naznačena time što je navedena rekombinantna stanica S. cerevisiae.
24. Imunogen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je namijenjen za primjenu u postupku liječenja ljudskog tijela putem terapije.
25. Imunogen prema patentnom zahtjevu 24, naznačen time što je namijenjen za osiguravanje zaštitnog imuniteta protiv S. aureus.
26. Imunogen prema patentnom zahtjevu 25, naznačen time što je navedeni pacijent čovjek.
27. Imunogen prema patentnom zahtjevu 25, naznačen time što se navedeni pacijent tretira profilaktički protiv S. aureus infekcije.
28. Imunogen prema patentnom zahtjevu 24, naznačen time što je namijenjen za indukciju anamnestičkog odgovora.
29. Imunogen prema patentnom zahtjevu 28, naznačen time što navedeni anamnestički odgovor ima za rezultat najmanje 3-struko povećanje u geometrijskom titru u odnosu na prethodni titar u roku od 3 dana.
30. Primjena imunogena prema bilo kojem od patentnih zahtjeva 1 do 12, naznačena time što je namijenjena za proizvodnju lijeka za primjenu u postupku kao što je definirano u bilo kojem od patentnih zahtjeva 25 do 29.
31. Imunogen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je u kombinaciji sa dodatnim imunogenima koji su izabrani iz grupe koju čine: jedan ili više dodatnih imunogena S. aureus; jedan ili više imunogena koji ciljano djeluju na jedan ili više drugih organizama Staphylococcus; i jedan ili više imunogena koji ciljano djeluju na druge infektivne organizme.
HR20100240T 2003-07-24 2010-04-26 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus HRP20100240T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
HRP20100240T1 true HRP20100240T1 (hr) 2010-09-30

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100240T HRP20100240T1 (hr) 2003-07-24 2010-04-26 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (hr)
EP (1) EP1651166B8 (hr)
JP (1) JP2007502101A (hr)
KR (1) KR20060065643A (hr)
AT (1) ATE457737T1 (hr)
AU (1) AU2004258979B2 (hr)
BR (1) BRPI0412799A (hr)
CA (1) CA2532370A1 (hr)
CY (1) CY1110028T1 (hr)
DE (1) DE602004025579D1 (hr)
DK (1) DK1651166T3 (hr)
ES (1) ES2342778T3 (hr)
HR (1) HRP20100240T1 (hr)
IL (1) IL173253A0 (hr)
IS (1) IS8213A (hr)
MX (1) MXPA06000854A (hr)
NO (1) NO20060898L (hr)
NZ (2) NZ544542A (hr)
PL (1) PL1651166T3 (hr)
PT (1) PT1651166E (hr)
RU (1) RU2337108C2 (hr)
SI (1) SI1651166T1 (hr)
WO (1) WO2005009379A2 (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1725575B1 (en) * 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20070085457A (ko) * 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 IsdA, IsdB, 및 IsdC 기재 백신,조성물 및 방법
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007210170A1 (en) * 2006-01-27 2007-08-09 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting S. aureus ORF0657n
CA2675992A1 (en) 2007-01-24 2008-11-20 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus epidermidis
EP1987836B1 (en) * 2007-05-04 2011-12-21 Martin Krönke Protective staphylococcus aureus vaccine based on cell wall-associated proteins
CN101679516B (zh) * 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
JP2012509665A (ja) 2008-11-26 2012-04-26 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・アウレウス(staphylococcusaureus)に対する防御免疫応答を誘導するポリペプチド
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 A(SpA) 변이체와 관련된 조성물 및 방법
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Staphylococcus.aureus5型および8型莢膜多糖の結合体
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (en) * 2010-03-12 2014-01-08 Univ Pennsylvania METHODS FOR PREVENTING AND TREATING COLONIZATION, STAPHYLOCOCCUS AUREUS-INDUCED INFECTION AND DISEASE
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
EP2593133A4 (en) 2010-07-13 2014-11-26 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
IN2014CN02152A (hr) 2011-09-01 2015-09-04 Novartis Ag
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP2320233A1 (en) * 2001-06-15 2011-05-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
ES2322338T3 (es) * 2001-11-12 2009-06-19 Novo Nordisk A/S Purificacion de peptidos por medio de cromatografia de afinidad con iones metalicos.
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
JP2007502101A (ja) 2007-02-08
CY1110028T1 (el) 2015-01-14
IS8213A (is) 2005-12-30
IL173253A0 (en) 2006-06-11
PL1651166T3 (pl) 2010-08-31
AU2004258979B2 (en) 2007-12-06
NZ570750A (en) 2009-12-24
RU2337108C2 (ru) 2008-10-27
MXPA06000854A (es) 2006-03-30
CA2532370A1 (en) 2005-02-03
WO2005009379A3 (en) 2006-11-30
RU2006105498A (ru) 2006-09-10
EP1651166B1 (en) 2010-02-17
KR20060065643A (ko) 2006-06-14
DE602004025579D1 (de) 2010-04-01
ATE457737T1 (de) 2010-03-15
NZ544542A (en) 2009-01-31
EP1651166A2 (en) 2006-05-03
EP1651166A4 (en) 2008-03-05
EP1651166B8 (en) 2010-05-19
NO20060898L (no) 2006-04-24
AU2004258979A1 (en) 2005-02-03
US20060177462A1 (en) 2006-08-10
US20100247561A1 (en) 2010-09-30
WO2005009379A2 (en) 2005-02-03
PT1651166E (pt) 2010-04-23
SI1651166T1 (sl) 2010-06-30
ES2342778T3 (es) 2010-07-14
BRPI0412799A (pt) 2006-09-26
DK1651166T3 (da) 2010-05-31

Similar Documents

Publication Publication Date Title
HRP20100240T1 (hr) Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
JP2007502101A5 (hr)
Baratova et al. The organization of potato virus X coat proteins in virus particles studied by tritium planigraphy and model building
JP2009540801A5 (hr)
EP1578922A2 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
IL172396A (en) CORONA virus peptides, a vaccine against the CORONA virus that contains them, methods for identifying and using them
AU2002309514A1 (en) Replikin peptides and uses thereof
PH12021550030A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
RU2014126587A (ru) Химерная частица hpv
JP7146926B2 (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
CA3233697A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
HRP20100340T1 (hr) Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju
TW200716166A (en) Lawsonia intracellularis immunological proteins
KR100906102B1 (ko) 레플리킨 펩타이드 및 그의 이용
EP1419175A2 (en) Replikin peptides and uses thereof
ES2366176T3 (es) Citocinas aviares novedosas y secuencias genéticas que codifican para las mismas.
IE871169L (en) Vaccine against varicella-zoster virus
CN102612559B (zh) 源自流感m2的修饰的肽疫苗
CN106480070A (zh) 一种用于展示目的多肽的多肽载体及其用途
JPS59501866A (ja) 腸内ウイルスに対するワクチン接種に有用なポリペプチド
KR101635673B1 (ko) A형 간염 바이러스 백신 소재 단백질 vp1-3n 및 백신 조성물
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
KR102647829B1 (ko) 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법
CN116262781A (zh) 抗菌肽defensin衍生物及其原核表达方法与应用
CN113248576A (zh) 一种针对冠状病毒的核酸疫苗及其制备方法